Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S144-S174
Open Access | Times Cited: 165

Showing 1-25 of 165 citing articles:

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1158
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 680
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Ian H. de Boer, Kamlesh Khunti, Tami Sadusky, et al.
Diabetes Care (2022) Vol. 45, Iss. 12, pp. 3075-3090
Open Access | Times Cited: 417
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 321
Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association
Rodica Pop‐Busui, James L. Januzzi, Dennis Bruemmer, et al.
Diabetes Care (2022) Vol. 45, Iss. 7, pp. 1670-1690
Open Access | Times Cited: 237
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Chengxu Ma, Xiaoni Ma, Conghui Guan, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 236
Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis
Xiao Liu, Ziqi Tan, Yuna Huang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 206
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 149
Periodontitis and implant complications in diabetes
Luigi Nibali, Nikolaos Gkranias, Giuseppe Mainas, et al.
Periodontology 2000 (2022) Vol. 90, Iss. 1, pp. 88-105
Open Access | Times Cited: 84
Ten things to know about ten cardiovascular disease risk factors – 2022
Harold Bays, Anandita Agarwala, Charles German, et al.
American Journal of Preventive Cardiology (2022) Vol. 10, pp. 100342-100342
Open Access | Times Cited: 82
Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs
Silviu Stanciu, Emilia Rusu, Daniela Miricescu, et al.
Metabolites (2023) Vol. 13, Iss. 1, pp. 87-87
Open Access | Times Cited: 54
Diabetes and restenosis
Scott Wilson, Pasquale Mone, Urna Kansakar, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 69
Management of Type 2 Diabetes Mellitus in Elderly Patients with Frailty and/or Sarcopenia
Jaime Sanz‐Cánovas, Almudena López‐Sampalo, Lidia Cobos-Palacios, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 14, pp. 8677-8677
Open Access | Times Cited: 58
Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2274-2274
Open Access | Times Cited: 54
High triglyceride-glucose index in young adulthood is associated with incident cardiovascular disease and mortality in later life: insight from the CARDIA study
Xinghao Xu, Rihua Huang, Yifen Lin, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 50
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
Vanita R. Aroda, Lawrence Blonde, Richard E. Pratley
Reviews in Endocrine and Metabolic Disorders (2022) Vol. 23, Iss. 5, pp. 979-994
Open Access | Times Cited: 49
Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes
Shi Tai, Liyao Fu, Ningjie Zhang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 46
Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities
Agnieszka Przezak, Weronika Bielka, Andrzej Pawlik
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6500-6500
Open Access | Times Cited: 45
Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy
Yiheng Pan, Pamela B. Davis, David C. Kaebler, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 44
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
João Sérgio Neves, Francisco Vasques‐Nóvoa, Marta Borges‐Canha, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 189-197
Open Access | Times Cited: 39
Statin initiation and risk of incident kidney disease in patients with diabetes
Shiyu Zhou, Licong Su, Ruqi Xu, et al.
Canadian Medical Association Journal (2023) Vol. 195, Iss. 21, pp. E729-E738
Open Access | Times Cited: 32
Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021
Mariam Elmegaard Malik, Alexander Christian Falkentoft, J. Steen Jensen, et al.
The Lancet Regional Health - Europe (2023) Vol. 29, pp. 100617-100617
Open Access | Times Cited: 31
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
Ildiko Lingvay, Ofri Mosenzon, Katelyn Brown, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 30
Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis
Qin Zhang, Siyuan Zhou, Lijun Liu
Diabetology & Metabolic Syndrome (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 30
Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression
José M. Rodriguez‐Valadez, Malak Tahsin, Kirsten E. Fleischmann, et al.
Diabetes Care (2023) Vol. 46, Iss. 6, pp. 1300-1310
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top